CGN Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

CGN Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,018	Closed	-$226K	–	215
2021 Q3	$226K	Hold	3,018	–	–	0.07%	186
2021 Q2	$279K	Hold	3,018	–	–	0.09%	178
2021 Q1	$268K	Sell	3,018 -1,406	-32%	-$139K	0.1%	171
2020 Q4	$413K	Buy	+4,424	New	+$352K	0.17%	126

Other funds holding ARKG

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

CGN Advisors's ARKG Position: Q4 2021 in Review

CGN Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,018 shares — an estimated $226K sold.

CGN Advisors first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $413K in Q4 2020. 462 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

CGN Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
CGN Advisors sold 3,018 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $226K.
CGN Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
CGN Advisors's ARK Genomic Revolution ETF position peaked at $413K in Q4 2020.
462 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on CGN Advisors's 13F filing for Q4 2021, filed 14 Jan 2022.